日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome

FBXO11抑制重塑以NPM1为中心的相互作用组,从而影响骨髓增生异常综合征的进展。

Niederkorn, Madeline; Bezavada, Lavanya; Cotton, Anitria; Palmer, Lance E; Konada, Lahiri; Hall, Trent; Pagala, Vishwajeeth R; Zhai, Jinbin; Yuan, Zuo-Fei; Fu, Yingxue; Steele, Jacob A; Narina, Shilpa; Schild, Andrew; Wu, Chengzhou; Aminov, Sarah; Schieber, Michael; McGovern, Erin; Taylor, Aaron B; Gurbuxani, Sandeep; Xu, Peng; Ji, Peng; Janke, Laura J; High, Anthony A; Kang, Guolian; Pruett-Miller, Shondra M; Weiss, Mitchell; Verma, Amit; Rampal, Raajit K; Crispino, John D

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review

在骨髓纤维化复杂情况下选择JAK抑制剂:综述

Vachhani, Pankit; Mesa, Ruben; Mascarenhas, John; Rampal, Raajit; Oh, Stephen T; Vannucchi, Alessandro Maria; Fox, Maria Laura; Palandri, Francesca; Passamonti, Francesco; Kiladjian, Jean-Jacques; Azimi, Mahshid; Harrison, Claire; Bose, Prithviraj

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib

POIESIS:一项针对对鲁索替尼反应欠佳的JAK抑制剂初治骨髓纤维化患者的附加navtemadlin III期研究

Vachhani, Pankit; Yacoub, Abdulraheem; Rampal, Raajit; Bradley, Terrence; Harrison, Claire; Jain, Tania; Kuykendall, Andrew; Palandri, Francesca; Mascarenhas, John; Al-Ali, Haifa; Passamonti, Francesco; Rothbaum, Wayne; Verstovsek, Srdan; Heidel, Florian H

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Pelabresib联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化:一项随机3期试验

Rampal, Raajit K; Grosicki, Sebastian; Chraniuk, Dominik; Abruzzese, Elisabetta; Bose, Prithviraj; Gerds, Aaron T; Vannucchi, Alessandro M; Palandri, Francesca; Lee, Sung-Eun; Gupta, Vikas; Lucchesi, Alessandro; Oh, Stephen T; Kuykendall, Andrew T; Patriarca, Andrea; Álvarez-Larrán, Alberto; Mesa, Ruben; Kiladjian, Jean-Jacques; Talpaz, Moshe; Scandura, Joseph M; Lavie, David; Harris, Morgan; Kays, Sarah-Katharina; Li, Qing; Boxhammer, Rainer; Brown, Barbara; Jegg, Anna-Maria; Harrison, Claire N; Mascarenhas, John

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition

RAF非依赖性MEK突变驱动难治性组织细胞肿瘤,但对ERK抑制剂有反应。

Eli L Diamond ,Jean-Francois Emile ,Takeshi Fujino ,Julien Haroche ,Maxim I Maron ,Alexander M Lewis ,Jahan Rahman ,Anne S Reiner ,Dana Bossert ,Marc Rosenblum ,Mariko Yabe ,Kseniya Petrova-Drus ,Jasmine H Francis ,Veronica Rotemberg ,Raajit K Rampal ,Sarah Yoo ,Anthony F Daniyan ,Sonia Mahajan ,Vaios Hatzoglou ,Robert Young ,Gary A Ulaner ,Wiebke Rösler ,Oshrat Hershkovitz-Rokah ,Ofer Shpilberg ,Roei D Mazor ,Luke Y C Chen ,Michael Singer ,M Adriana Cuibus ,Kenyon Weis ,Salima Benbarche ,Pu Zhang ,Nina Fox ,Cynthia Castro ,Steven Tittley ,Matthew Witkowski ,Fleur Cohen-Aubart ,Louis Terriou ,Maher Hanoun ,Nicolas Schleinitz ,Gabriela Sosa ,Timo Hautala ,Laure Farnault De Lassus ,Neal Rosen ,Omar Abdel-Wahab ,Benjamin H Durham

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML

新型 BCL-xL 降解剂 DT2216 在 JAK2 突变型 MPN 后 AML 临床前模型中的疗效

Wang, Zhe; Skwarska, Anna; Poigaialwar, Gowri; Chaudhry, Sovira; Rodriguez-Meira, Alba; Sui, Pinpin; Olivier, Emmanuel; Jia, Yannan; Gupta, Varun; Fiskus, Warren; Ramage, Cassandra L; Zheng, Guangrong; Schurer, Alexandra; Gritsman, Kira; Papapetrou, Eirini P; Bhalla, Kapil; Zhou, Daohong; Mead, Adam J; Rampal, Raajit K; Tyner, Jeffrey W; Abbas, Hussein A; Pemmaraju, Naveen; Tatarata, Qi Zhang; Konopleva, Marina

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

CDK7抑制剂联合疗法对转化为AML的骨髓增生性肿瘤的临床前疗效

Fiskus Warren, Mill Christopher P, Bose Prithviraj, Masarova Lucia, Pemmaraju Naveen, Dunbar Andrew, Birdwell Christine E, Davis John A, Das Kaberi, Hou Hanxi, Manshouri Taghi, Jain Antrix, Malovannaya Anna, Philip Kevin, Alhamadani Noor, Matthews Alicia, Lin Katie, Flores Lauren B, Loghavi Sanam, DiNardo Courtney, Su Xiaoping, Rampal Raajit K, Bhalla Kapil N

Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia

双重靶向 EZH2 和 EZH1 可促使白血病干细胞退出静止状态,并增强急性髓系白血病的化疗效果。

Akiyama, Hiroki; Nishida, Yuki; Chang, Kyung Hee; Bedoy, Andrea D; Muftuoglu, Muharrem; Ma, Wencai; Basyal, Mahesh; Hirschi, Zoe; Honma, Daisuke; Tsutsumi, Shinji; Wang, Jing; Zhang, Weiguo; Huang, Xuelin; Rampal, Raajit K; Oluwole, Olalekan O; Bixby, Dale Lee; Daver, Naval G; Andreeff, Michael

Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia

预防和治疗骨髓增生性肿瘤向急性髓系白血病的转化

Patel, Anand A; Rampal, Raajit K

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy

评估接受低强度治疗的加速期/急变期骨髓增生性肿瘤患者的基于急性髓系白血病(AML)的风险标准

Shaw, Reid; Yoon, James J; Johnston, Hannah; Davidson, Marta B; Siddon, Alexa J; Shallis, Rory M; Chen, Evan C; Burkart, Madelyn; Oh, Timothy S; Iyer, Sunil G; Madarang, Ellen; Muthiah, Chandrasekar; Kassner, Joshua; Rampal, Raajit K; Guru Murthy, Guru Subramanian; Bradley, Terrence; Abaza, Yasmin; Garcia, Jacqueline S; Gupta, Vikas; Pettit, Kristen M; Odenike, Olatoyosi; Patel, Anand A